Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease

NCT02079246 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT02079246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02079246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease
Lead sponsor
H. Lundbeck A/S
Phase
Phase 3
Overall status
Completed
Start date
April 7, 2014
Completion date
July 6, 2017
Enrollment
1,463 (actual)
Sites
258

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease